Genmab — Marts 2020

[nohope]

Neeeeeej -

[royal]

Min siger 5,53

[royal]

Genmab A/S (GMAB) Stock Price, News, Quote & History - Yahoo Finance

Find the latest Genmab A/S (GMAB) stock quote, history, news and other vital information to help you with your stock trading and investing.

Yahoo Finance (finance.yahoo.com)

[nohope]

Jeg burde have skrevet at jeg referede til DJ - beklager

[bikube]

24,04$ Hvad er kursen på $ idag?

[nohope]

6,71

[nohope]

161,30

[nohope]

• men det er ikke US der sætter kursen i DK.

[Jazzz]

Er der slet
ingen der er nervøse for Sanofi godk overhovedet?

[bibob]

God morgen.

[transalp]

Go morgen..

[Helge_LarsenPI-redaktør]

Vincent Rajkumar
@VincentRK
·
7 t
Today @US_FDA
@FDAOncology
approved isatuximab (Sarclisa) for relapsed refractory myeloma.

Im happy that @SanofiUS
has priced it significantly lower than daratumumab. I hope there is a price war, & prices drop more. Based on cost, I’ll prefer Isa-PomDex to Dara-PomDex. @mtmdphd

[Helge_LarsenPI-redaktør]

Vincent Rajkumar
@VincentRK
·
7 t
I was an author on the isatuximab pivotal trial. Im working with both @sanofi
and @JanssenUS
on other trials.

Look forward to thoughts on how we support the appropriate choice of drug taking cost into account from @Rfonsi1
@akeithstewart
@peterbachmd
& others who are interested

[E_L]

#ACTRIMS2020 – Results of Ofatumumab Self-injection Pen Equivalent to Infusion, APLIOS Trial Shows https://multiplesclerosisnewstoday.com/news-posts/2020/02/28/actrims2020-poster-session-lb300-onset-of-b-cell-depletion-with-subcutaneous-administration-of-ofatumumab-in-relapsing-multiple-sclerosis-results-from-the-aplios-bioequivalence-study

[E_L]

CureVac still in the Coronavirus Vaccine race https://www.globenewswire.com/news-release/2020/03/02/1993888/0/en/CureVac-CEO-Daniel-Menichella-Discusses-Coronavirus-Vaccine-Development-with-U-S-President-Donald-Trump-and-Members-of-Coronavirus-Task-Force.html

[bibob]

Karyopharm. https://www.statnews.com/2020/03/02/karyopharm-to-seek-expanded-use-of-multiple-myeloma-drug-following-positive-clinical-trial/

[Vitus]

Tegner til en forrygende åbning

[lahn1]

Godt spg, Jazzz 23:14, Er det EQUULEUS vi skal sammenligne med ?

[Sukkeralf]

Det største problem med Sanofi er, at pt sælger Genmab mest med Daratumumab i kombination med POM-DEX, så det er lidt samme patientgrundlag. Tilsyneladende er denne kombi ogås meget brugt i anden linie, så spørgsmålet er om Sanofi også kan vinde indpas der med en lavere prissætning. Lad os håbe at sc dosering er en game changer som Jan siger - omvendt kan Sanofi indpas gøre det svært for JNJ at hæve prisen pt.

[Sukkeralf]

Karyopharm henter penge igen